Concurrent locomotor stimulation and decrease in dopamine release in rats and mice after treatment with the competitive NMDA receptor antagonists D-CPPene and CGS 19755

Journal of Neural Transmission

Volumn 103, Issue 1-2, 1996, Pages 117-129

  Waters, N ^a   Lundgren, C ^a   Hansson, L O ^a   Carlsson, M L ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Competitive nmda antagonists; Dopamine; Glutamate; Psychosis; Release

Indexed keywords

3 O METHYLDOPAMINE; 4 (3 PHOSPHONOALLYL) 2 PIPERAZINECARBOXYLIC ACID; 4 PHOSPHONOMETHYLPIPECOLIC ACID; 5 HYDROXYINDOLEACETIC ACID; HOMOVANILLIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DIALYSATE; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DRUG EFFECT; FOREBRAIN; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MICRODIALYSIS; MONOAMINERGIC SYSTEM; MOTOR ACTIVITY; MOUSE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONIN BRAIN LEVEL;

ANIMALS; BRAIN CHEMISTRY; DOPAMINE; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MICE; MICRODIALYSIS; MOTOR ACTIVITY; PIPECOLIC ACIDS; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; SPECIES SPECIFICITY;

EID: 0030070978     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01292621     Document Type: Article

References (38)

1. Angrist B (1987) Pharmacological models of schizophrenia. In: Henn FA, DeLisi LE (eds) Handbook of schizophrenia, vol 2. Neurochemistry and neuropharmacology of schizophrenia. Elsevier, Amsterdam, pp 391-424
2. Bubser M, Keseberg U, Notz PK, Schmidt WJ (1992) Differential behavioural and biochemical effects of competitive and non-competitive NMDA receptor antagonists in rats. Eur J Pharmacol 229: 75-82
3. Carlsson A, Lindqvist M (1973) Effect of ethanol on the hydroxylation of tyrosine in rat brain in vivo. J Pharm Pharmacol 25: 437-440
4. Carlsson A (1988) The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1: 179-186 (+ Comments by Meltzer HY)
5. Carlsson ML (1993) Hypothesis - Are the disparate pharmacological profiles of competitive and un-competitive NMDA antagonists due to different baseline activities of distinct glutamatergic pathways? J Neural Transm [GenSect] 94: 1-10
6. Commissiong JW (1985) Monoamine metabolites: their relationship and lack of relationship to monoaminergic neuronal activity. Biochem Pharmacol 34: 1127-1131
7. Crespi F, Garratt JC, Sleigh AJ, Marsden CA (1990) In vivo evidence that 5-hydroxytryptamine (5-HT) neuronal firing and release are not necessarily correlated with 5-HT metabolism. Neuroscience 35: 139-144
8. Delgado JMR, DeFeudis FV, Roth RH, Ryugo DK, Mitruka BM (1972) Dialytrode for long term intracerebral perfusion in awake monkeys. Arch Int Pharmacodyn 198: 9-21
9. Engström G, Svensson TH, Waldeck B (1974) Thyroxine and brain catecholamines increased transmitter synthesis and increased receptor sensitivity. Brain Res 72: 471-483
10. Galloway MP, Bencloucif S, Keegan MJ (1992) Effects of excitatory amino acid manipulation on serotonin facilitation of DA release on vivo microdialysis. Excitatory Amino Acids, Yosemite, California (Abstract, p 19)
11. Hansson LO, Waters N, Winblad B, Gottfries CG, Carlsson A (1994) Evidence for biochemical heterogeneity in schizophrenia: a multivariate study of monoaminergic indices in human post-mortal tissue. J Neural Transm [GenSect] 98: 217-235
12. Hiramatsu M, Cho AK, NabeshimaT (1989) Comparison of the behavioral and biochemical effects of the NMDA receptor antagonists, MK-801 and phencyclidine. Eur J Pharmacol 166: 359-366
13. Javitt DC (1987) Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J Clin Psych 9: 12-33
14. Kehr W (1976) 3-Methoxytyramine as an indicator of impulse-induced dopamine release in rat brain in vivo. Naunyn Schmiedebergs Arch Pharmacol 293: 209-215
15. Keefe KA, Zigmond MJ, Abercrombie ED (1993) In vivo regulation of extracellular dopamine in the neostriatum: influence of activity and local excitatory amino acids. J Neural Transm [GenSect] 91: 223-240
16. Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmüller B (1980) Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 20: 379-382
17. Krnjevic K, Lamour Y, Macdonald JF, Nistri A (1978) Intracellular actions of monoamine transmitters. Can J Physiol Pharmacol 56: 896-900
18. Leviel V, Gobert A, Guibert B (1990) The glutamate-mediated release of dopamine in the rat striatum: further characterization of the dual excitatory-inhibitory function. Neuroscience 39: 305-312
19. Liljequist S, Ossowska K, Grabowska-Andén, Andén N-E (1991) Effect of the NMDA receptor antagonist, MK-801, on locomotor activity and on the metabolism of dopamine in various brain areas of mice. Eur J Pharmacol 195: 55-61
20. Lillrank SM, O'Connor WT, Oja SS, Ungerstedt U (1994) Systemic phencyclidine administration is associated with increased dopamine, GABA, and 5-HIAA levels in the dorsolateral striatum of conscious rats: an in vivo microdialysis study. J Neural Transm [GenSect] 95: 145-155
21. Lodge D, Johnson KM (1990) Noncompetitive excitatory amino acid receptor antagonists. Trends Pharmacol Sei 11: 81-86
22. Löscher W, Annies R, Hönack D (1991) The N-methyl-D-aspartate antagonist MK-801 induces increases in dopamine and serotonin metabolism in several brain regions of rat. Neurosci Lett 128: 191-194
23. Löscher W, Annies R, Hönack D (1993) Comparison of competitive and uncompetitive NMDA receptor antagonists with regard to monoaminergic neuronal activity and behavioral effects in rats. Eur J Pharmacol 242: 263-274
24. Martin GE (1986) Catecholamine release within the striatum of the freely moving rat. Ann NY Acad Sei 473: 151-159
25. Meldrum BS, Kerwin RW (1987) Glutamate receptors and schizophrenia. J Psychopharmacol 1: 217-221
26. Miu P, Karoum F, Toffano G, Commissiong JW (1992) Regulatory aspects of nigrostriatal dopaminergic neurons. Exp Brain Res 91: 489-495
27. Moghaddam B, Gruen RJ (1991) Do endogenous exicatory amino acids influence striatal dopamine release. Brain Res 544: 329-330
28. Moghaddam B, Bunney BS (1989) Ionic composition of microdialysis perfusing solution alters the pharmacological responsiveness and basal outflow of striatal dopamine. J Neurochem 53: 652-665
29. Moghaddam B, Gruen RJ, Roth RH, Bunney BS, Adams RN (1990) Effect of Lglutamate on the release of striatal dopamine: in vivo dialysis and electrochemical studies. Brain Res 518: 55-60
30. Pawlowski L, Mathé JM, Svensson TH (1990) Phencyclidine activates rat A10 dopamine neurons but reduces burst activity and causes regularization of firing. Acta Physiol Scand 139: 529-530
31. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd ed. Academic Press, New York
32. Svensson A, Pileblad E, Carlsson M (1991) A comparison between the non-competitive NMDA antagonist dizocilpine (MK-801) and the competitive NMDA antagonist D-CPPene with regard to dopamine turnover and locomotor-stimulatory properties in mice. J Neural Transm [GenSect] 85: 117-129
33. Svensson K, Johansson AM, Magnusson T, Carlsson A (1986) (+)-AJ76 and (+)-UH232: central stimulants acting as preferential dopamine autoreceptor antagonists. Naunyn Schmiedebergs Arch Pharmacol 334: 234-245
34. Troupin AS, Mendius JR, Cheng F, Risinger MW (1986) In: Watkins JC, Collingridge GL (eds) New anticonvulsant drugs. John Libbey, London, pp 191-201
35. Waters N, Lagerkvist S, Löfberg L, Piercey M, Carlsson A (1993) The dopamine D3 receptor and autoreceptor preferring antagonists (+)-AJ76 and (+)-UH232; a microdialysis study. Eur J Pharmacol 242: 151-163
36. Westerink BHC, Justice JB (1991) Microdialysis compared with other in vivo release models. In: Robinson TE, Justice JB (eds) Microdialysis in thé neurosciences. Eisevier, Amsterdam London New York Tokyo, p 28
37. Weihmuller FB, O'Dell SJ, Cole BN, Marshall JF (1991) MK-801 attenuates the dopamine-releasing but not the behavioral effects of methamphetamine: an in vivo microdialysis study. Brain Res 549: 230-235
38. Zetterström T, Sharp T, Marsden CA, Ungerstedt U (1983) In vivo measurement of dopamine and its metabolites by intracerebral dialysis: changes after d-amphetamine. J Neurochem 41: 1769-1773